The Week in Review: June 2 – June 9, 2017

Friday, June 9, 2017 News Recap Somebody Pinch Me This week saw the release of a report from the Cochrane Collaboration which concluded not only that DAAs were ineffective but that they might also be bad for you and not even cure HCV.  The news item was picked up by various media outlets and was hard to miss (No valid evidence $40,000 miracle drug cures hepatitis C – study).  Thankfully other researchers from around the world jumped in on this poor ...

WHO recommends Epclusa, a Hepatitis C Combined Therapy in Just One Pill

A combined treatment for hepatitis C based on sofosbuvir and velpatasvir (brand name Epclusa) is among the additions to the World Health Organization (WHO) Model List of Essential Medicines (EML) for 2017. Velpatasvir is an antiviral drug that inhibits a viral protein called NS5A. This drug prevents the replication of the virus and the assembly of new virus particles. Sofosbuvir, which already was included in the previous EML, targets another protein in t

The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Nova Scotia: New drug will help with hepatitis C treatment

Nova Scotians will soon have access to a new drug to help treat hepatitis C. Nova Scotia’s Department of Health and Wellness announced Monday the province will provide public access to EPCLUSA tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C. With this drug, patients take one tablet daily for 12 weeks, provided they are adult patients without cirrhosis or with compensat

Alberta expands drug coverage for hepatitis C patients

“Effective April 2017, Alberta Health has agreed to pay for several new therapies for the treatment of hepatitis C, the most important of which is a medicine called Epclusa, which contains two anti-viral drugs,” said Stephen Shafran, a professor of medicine at the University of Alberta. Epclusa, a drug for hep C with a near 100 per cent cure rate, is now going to be covered by Alberta Health. “This should give people hope that they can be cured,” Shafr

British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic hepatitis C infection

-- British Columbia Also Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective March 21, 2017, British Columbia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C ...

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ (Quebec)

-- Quebec Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 20, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) commends the continued leadership of Quebec in the treatment of hepatitis C with the listing of EPCLUSA™ (sofosbuvir/velpatasvir) tablets effective on March 22, 2017.  EPCLUSA is the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with g...

London liver specialist urges people to get tested, treated, cured and move on with their lives because new drugs have a 98 per cent cure rate

The eradication of hepatitis C may be on the horizon. New, expensive drugs approved by the Ontario government mean new hope for those suffering from liver-destroying hepatitis C, a potentially fatal virus that many people don’t even know they have. The Ontario government has added six new hepatitis drugs to its Ontario Public Drug Programs that will help cure the 40 per cent of hepatitis sufferers who formerly were unable to access treatment. “It’s a v

The Week in Review: Feb 17, 2017 – Feb 24, 2017

Friday, February 24, 2017 News Recap Better Public Access to New HepC Meds Announced in Canada This week the pan-Canadian Pharmaceutical Alliance (pCPA), on behalf of participating federal, provincial and territorial public drug plans, concluded successful negotiations with three drug manufacturers to help jurisdictions expand access to publicly funded medications for the treatment of chronic hepatitis C. What this Means: Immediately following th...

Ontario Becomes First Province To List EPCLUSA™ On Public Drug Plan To Treat All Six Genotypes Of Chronic Hepatitis C Infection

Ontario Also Broadens Access for Patients with Less Advanced Disease with Co-Factors —MISSISSAUGA, ON, Feb. 22, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective February 28th, 2017, Ontario will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.  This listing